Physician profile
Luis A Nidea
NPI 1154311751
$3,140.10
in general payments reported to CMS, 2019-2025
24 companies · $496 in 2025
The $496 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.88 · 2022: $745 · 2023: $1,054 · 2024: $797 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,347.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $490.95 | 2022-2025 | |
| Celgene Corporation | $389.86 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $331.01 | 2022-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $308.29 | 2022-2025 | Stelara, Tremfya, Simponi |
| E.R. Squibb & Sons, L.L.C. | $241.69 | 2022-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $222.09 | 2022-2025 | Dupixent |
| Genzyme Corporation | $185.17 | 2022-2025 | |
| Medtronic, INC. | $126.17 | 2022-2024 | Gi Genius |
| Boston Scientific Corporation | $125.00 | 2024 | Watchman Flx |
| Pfizer INC. | $122.38 | 2019-2025 | |
| Madrigal Pharmaceuticals | $102.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $72.08 | 2022-2024 | Sutab, Suflave |
| Gilead Sciences, INC. | $68.53 | 2022-2024 | |
| Ardelyx, INC. | $57.65 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $54.49 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $51.52 | 2024-2025 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.56 | 2023 | Cyltezo |
| Qol Medical, LLC | $33.03 | 2025 | Sucraid |
| Lilly USA, LLC | $25.32 | 2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $21.42 | 2024 | Rebyota |
| Intercept Pharmaceuticals, INC. | $18.02 | 2024 | |
| Amgen INC. | $17.90 | 2025 | Uplizna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.35 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.98 | 2023 | Linzess |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Nidea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.